NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
Clinical Trials
27 trialsNCT02687958 2023-05-30
Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Unknown
NCT04355858 2022-07-26
MULAN
Fudan University
Phase 2 Unknown
NCT03239015 2022-03-04
Efficacy and Safety of Precision Therapy in Refractory Tumor
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT05124431 2021-11-18
ALTER-UC-001
Fudan University
Phase 2 Unknown
NCT01263951 2021-10-26
Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone
Thomas Jefferson University
Phase 2 Unknown
NCT02294006 2021-09-09
MetNET1
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT02695459 2021-04-20
Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin
The Netherlands Cancer Institute
Phase 2 Unknown
NCT02638428 2020-03-19
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Samsung Medical Center
Phase 2 Unknown
NCT02233049 2018-07-23
BIOMEDE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Unknown
NCT02836847 2018-05-07
Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Shanghai Jiao Tong University School of Medicine
Phase 2 Unknown
NCT01954693 2018-01-30
TRON
Cardiff University
Phase 2 Unknown
NCT01283789 2017-02-08
Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer
University of Kansas Medical Center
Phase 2 Unknown
NCT00499603 2016-11-01
Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Unknown
NCT02188550 2015-05-19
Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer
Sinai Hospital of Baltimore
Phase 2 Unknown
NCT01960829 2015-05-01
Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT02313051 2014-12-09
MIRACLE
ChineseAMS
Phase 2 Unknown
NCT02025712 2014-01-01
Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer
Organisation for Oncology and Translational Research
Phase 2 Unknown
NCT01118065 2013-08-12
Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01216826 2013-08-07
Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma
Hospital Santa Marcelina
Phase 2 Unknown
NCT01216839 2013-03-26
Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas
Hospital Santa Marcelina
Phase 2 Unknown
NCT00466102 2012-08-30
RADAR
GBG Forschungs GmbH
Phase 2 Unknown
NCT01423708 2012-07-18
EPOCAL
Azienda Ospedaliera di Padova
Phase 2 Unknown
NCT01088893 2012-05-24
Everolimus in Breast Cancer Patients After Pre-operative Chemotherapy
Organisation for Oncology and Translational Research
Phase 2 Unknown
NCT01525719 2012-02-03
CRAD001T
Ratchavithi Hospital
Phase 2 Unknown
NCT00973713 2009-09-09
RADiChol
Austin Health
Phase 2 Unknown
NCT00657982 2009-01-21
Phase II Study of RAD001 in a Neoadjuvant Setting in Men With Intermediate or High Risk Prostate Cancer
Sheba Medical Center
Phase 2 Unknown